- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Siemens Healthineers Launches New AI-Powered Ultrasound System
Providing 25 features to facilitate optimal workflow and user effectiveness, the portable Acuson Maple ultrasound can reportedly be utilized in a variety of clinical settings.
Combining ease of use, workflow enhancements and artificial intelligence (AI) -enabled features, Siemens Healthineers has launched the Acuson Maple ultrasound system.
Recently cleared by the Food and Drug Administration (FDA), the Acuson Maple ultrasound device has a variety of AI tools to mitigate repetitive tasks and streamline radiology workflows, according to Siemens Healthineers.
The company noted that the eSie Measure offers automated cardiac measurements, can facilitate up to a 44 percent reduction in keystrokes and shaves five minutes off the time it takes to complete routine echocardiography exams.
Another machine learning-based benefit is the Auto OB feature. Siemens Healthineers said this feature’s automated calculations of fetal age and weight account for a 24 percent reduction in the time it takes to perform fetal measurements on ultrasound exams.
Overall, the company noted that the battery-powered Acuson Maple system offers the capability of 75 minutes of unplugged scanning as well as 25 features for improving usability and ultrasound workflow.
“Siemens Healthineers proudly expands its Acuson portfolio with the Acuson Maple, which leverages a common hardware and software platform as well as AI-powered² applications that automate workflow and analysis to bolster exam efficiency,” said Daniel Frisch, head of radiology and image guidance at Siemens Healthineers Ultrasound. “This affordable, configurable, and versatile system offers a broad range of diagnostic imaging capabilities, with a high level of image quality for every patient.”
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
